Recombinant Factor VIIa for the Prophylaxis of Perioperative Hemorrhage in a Patient With Congenital Factor XI Deficiency Undergoing Brain Tumor Neurosurgery
Free accessOtherFirst published online October, 2008
Recombinant Factor VIIa for the Prophylaxis of Perioperative Hemorrhage in a Patient With Congenital Factor XI Deficiency Undergoing Brain Tumor Neurosurgery
The authors report on the first successful use of recombinant activated factor VII for the prophylaxis of bleeding during brain tumor neurosurgery in a patient suffering from inherited factor XI deficiency. Using the agent, surgery was performed without any bleeding complications. In this setting, off-label use of recombinant activated factor VII appears to be a promising alternative for patients suffering from this rare hemostatic defect with hitherto limited therapeutic options.
Hedner U.Mechanism of action of recombinant activated factor VII: an update. Semin Hematol. 2006;43 (1 Suppl): 105-107.
2.
Batorova A., Lazur J., Cupanik V., Kotoucek P., Mistrik M.Successful treatment of postoperative bleeding with continuous infusion of recombinant factor VIIa in patient with severe factor XI deficiency and allergic reactions to plasma [abstract]. Thromb Haemost. 1999;621(Suppl): 1955.
3.
Bern M., Sahud M., Zhukov O., Qu K., Mitchell W. Jr.Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia. 2005;11:20-25.
4.
Billon S., LeNiger C., Escoffre-Barbe M., Vicariot M., Abgrall JFThe use of recombinant factor VIIa (NovoSeven®) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis. 2001;12:551-553.
5.
Brown SAWhat dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia. 2005;11:430-431.
6.
Castillo R.Patients treated on a compassionate use basis-case histories: in FXI deficiency . In: Hedner U, Roberts HR, eds. 2nd Symposium on New Aspects of Hemophilia Treatment. Bussum, Netherlands: Medicom Europe; 1991:137-139.
7.
Lawler P., White B., Pye S., et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia . 2002;8:145-148.
8.
O'Connell NMFactor XI deficiency-from molecular genetics to clinical management. Blood Coagul Fibrinolysis. 2003;14(1 Suppl):59-64.
9.
Schulman S., Nemeth H.An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia. 2006;12:223-227.
10.
Salomon O., Seligsohn U.New observations on factor XI deficiency. Haemophilia. 2004;(4 Suppl):184-187.
11.
O'Connell NMFactor XI deficiency. Semin Hematol. 2004;41(1 Suppl):76-81.
12.
Salomon O., Zivelin A., Livnat T., et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood. 2003; 101:4783-4788.
13.
Bolton-Maggs PH, Colvin BT, Satchi BT, Lee CA, Lucas GAThrombogenic potential of factor XI concentrate . Lancet. 1994;344:748-749.
14.
Gitel SN, Caron D., Schulman S., Martinowitz U.Clinical experiences of a F XI concentrate: possible side-effects. Thromb Haemost. 1991;65:1157.
15.
Salomon O., Zivelin A., Livnat T., Seligsohn U.Inhibitors to Factor XI in patients with severe Factor XI deficiency. Semin Hematol. 2006;43(1 Suppl):10-12.
16.
Brodsky JB, Burgess GE III.Pulmonary embolism with factor XI deficiency. JAMA. 1975;234:1156-1157.
17.
Mayer SA, Brun NC, Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage . N Engl J Med. 2005;352:777-785.
